Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

• Thomas Martin,
• Meletios-Athanasios Dimopoulos,
• Joseph Mikhael,
• Kwee Yong,
• Marcelo Capra,
• Thierry Facon,
• Roman Hajek,
• Ivan Špička,
• Ross Baker,
• Kihyun Kim,
• Gracia Martinez,
• Chang-Ki Min,
• Ludek Pour,
• Xavier Leleu,
• Albert Oriol,
• Youngil Koh,
• Kenshi Suzuki,
• France Casca,
• Sandrine Macé,
• Marie-Laure Risse,
• Philippe Moreau

Affiliations

Thomas Martin

Department of Hematology, University of California at San Francisco

Meletios-Athanasios Dimopoulos

The National and Kapodistrian University of Athens

Joseph Mikhael

Translational Genomics Research Institute, City of Hope Cancer Center

Kwee Yong

Department of Haematology, University College Hospital

Marcelo Capra

Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus

Thierry Facon

Department of Haematology, Lille University Hospital

Roman Hajek

Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava

Ivan Špička

Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital

Ross Baker

Perth Blood Institute, Murdoch University

Kihyun Kim

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Gracia Martinez

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Chang-Ki Min

Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea

Ludek Pour

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno

Xavier Leleu

Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm

Albert Oriol

Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias I Pujol

Youngil Koh

Department of Internal Medicine, Seoul National University Hospital

Kenshi Suzuki

Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center

France Casca

Ividata Life Science

Sandrine Macé

Sanofi, R&D

Marie-Laure Risse

Sanofi, R&D

Philippe Moreau

Department of Hematology, University Hospital Hôtel-Dieu